FORT WORTH, Texas, April 16 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc. announced today that its CellerateRx product, distributed through its subsidiary Wound Care Innovations, LLC, will be highlighted in a presentation at the 23rd Annual Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS) meeting April 17-20 in Orlando, Florida. The presentation is "Activated Collagen Accelerates Wound Repair and Modulates Cytokine Production in Whole Blood and PBMC Cultures" by Gregory B. Pott, K. Scott Beard, Matthew Regulski, and Leland Shapiro. This is the largest annual gathering of wound care clinicians in the United States, with more than 2000 physicians, podiatrists, nurses, therapists, and researchers registered to attend. It provides attendees with state-of-the-art information on clinical problems and the exhibit hall provides them information about innovative products and emerging technologies in wound care. One of the most popular aspects of the conference is the poster and oral abstract session which offers unique educational benefits to attendees. In addition, Wound Care Innovations will also be showcasing its complete line of activated collagen wound care products as an exhibitor at this year's conference.
Wound Care Innovations also announced the expansion of their sales team with the addition of three full time business development managers in Florida. All are seasoned sales professionals with experience in the wound care market. "I am delighted that we will have in attendance at SAWC the initial members of the Florida team. We look forward to the growth of our product placements in Florida as we continue to grow nationally and internationally," says Ronald D. Mathis, SR VP of Marketing & Sales.
About Wound Care Innovations, LLC
Wound Care Innovations, LLC (WCI) is a wholly owned subsidiary of Wound Management Technologies, Inc. with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida. WCI markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on CellerateRx, please visit the WCI web site at www.CellerateRx.com .
Safe Harbor Statement:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
Wound Management Technologies, Inc.
